Literature DB >> 28648400

Oesophageal cancer.

Jesper Lagergren1, Elizabeth Smyth2, David Cunningham2, Pernilla Lagergren3.   

Abstract

Oesophageal cancer is a clinically challenging disease that requires a multidisciplinary approach. Extensive treatment might be associated with a considerable decline in health-related quality of life and yet still a poor prognosis. In recent decades, prognosis has gradually improved in many countries. Endoscopic procedures have increasingly been used in the treatment of premalignant and early oesophageal tumours. Neoadjuvant therapy with chemotherapy or chemoradiotherapy has supplemented surgery as standard treatment of locally advanced oesophageal cancer. Surgery has become more standardised and centralised. Several therapeutic alternatives are available for palliative treatment. This Seminar aims to provide insights into the current clinical management, ongoing controversies, and future needs in oesophageal cancer.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28648400     DOI: 10.1016/S0140-6736(17)31462-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  254 in total

1.  Integrative analysis of differential circular RNA and long non-coding RNA profiles and associated competing endogenous RNA networks in esophageal squamous cell carcinoma.

Authors:  Jiang-Feng Shen; Jin-Feng Ge; Shi-Ying Zheng; Dong Jiang
Journal:  Funct Integr Genomics       Date:  2021-01-07       Impact factor: 3.410

2.  Prognostic and predictive values of interim 18F-FDG PET during neoadjuvant chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis.

Authors:  Sangwon Han; Yong-Il Kim; Sungmin Woo; Tae-Hyung Kim; Jin-Sook Ryu
Journal:  Ann Nucl Med       Date:  2021-01-20       Impact factor: 2.668

3.  Stereotactic body radiation therapy and thymosin alpha-1-induced anti-tumor effects in heavily pretreated, metastatic esophageal squamous cell carcinoma patients.

Authors:  Dexi Du; Tao Song; Hui Dai; Zhao Jing; Peng Chen; Shixiu Wu
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110

4.  The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study.

Authors:  George Papaxoinis; Konstantinos Kamposioras; Jamie M J Weaver; Zoe Kordatou; Sofia Stamatopoulou; Theodora Germetaki; Magdy Nasralla; Vikki Owen-Holt; Alan Anthoney; Wasat Mansoor
Journal:  J Gastrointest Surg       Date:  2019-01-22       Impact factor: 3.452

Review 5.  Radiomics in Oncological PET/CT: Clinical Applications.

Authors:  Jeong Won Lee; Sang Mi Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-10-20

Review 6.  Esophageal carcinoma: Towards targeted therapies.

Authors:  Ali Fatehi Hassanabad; Rania Chehade; Daniel Breadner; Jacques Raphael
Journal:  Cell Oncol (Dordr)       Date:  2019-12-17       Impact factor: 6.730

7.  Should cT2 esophageal cancer get neoadjuvant treatment before surgery?

Authors:  Peter Thuss-Patience; Loredana Vecchione; Ulrich Keilholz
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

8.  Risk of Esophageal Adenocarcinoma After Antireflux Surgery in Patients With Gastroesophageal Reflux Disease in the Nordic Countries.

Authors:  John Maret-Ouda; Karl Wahlin; Miia Artama; Nele Brusselaers; Martti Färkkilä; Elsebeth Lynge; Fredrik Mattsson; Eero Pukkala; Pål Romundstad; Laufey Tryggvadóttir; My von Euler-Chelpin; Jesper Lagergren
Journal:  JAMA Oncol       Date:  2018-11-01       Impact factor: 31.777

9.  HIPK2 inhibits cell metastasis and improves chemosensitivity in esophageal squamous cell carcinoma.

Authors:  Zhen Zhang; Penghai Wen; Fangfang Li; Chuanshan Yao; Tongfu Wang; Bing Liang; Qingle Yang; Lei Ma; Limin He
Journal:  Exp Ther Med       Date:  2017-11-08       Impact factor: 2.447

10.  Recent advances in defining and benchmarking complications after esophagectomy.

Authors:  Lucas Goense; Jelle P Ruurda; Richard van Hillergersberg
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.